Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $865,000 Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,466 shares of the biotechnology company’s stock after purchasing an additional 645 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in ADMA Biologics were worth $865,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp grew its holdings in ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after acquiring an additional 4,945,063 shares during the last quarter. Perpetual Ltd acquired a new position in shares of ADMA Biologics during the fourth quarter worth $62,300,000. Lord Abbett & CO. LLC bought a new stake in shares of ADMA Biologics in the third quarter worth $61,858,000. Allspring Global Investments Holdings LLC increased its holdings in ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after purchasing an additional 2,613,482 shares during the period. Finally, Raymond James Financial Inc. bought a new position in ADMA Biologics during the 4th quarter worth $19,076,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.70 on Thursday. The company has a market capitalization of $4.66 billion, a PE ratio of 70.36 and a beta of 0.60. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $5.90 and a twelve month high of $23.64. The firm has a fifty day simple moving average of $16.97 and a 200 day simple moving average of $18.11.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.